Population-level effectiveness & cost-effectiveness of the 9-valent HPV vaccine
|
|
- Charles Bradford
- 5 years ago
- Views:
Transcription
1 Population-level effectiveness & cost-effectiveness of the 9-valent HPV vaccine Marc Brisson Canadian Research Chair Modeling Infectious Diseases Associate Professor, Université Laval PCC2015 February 21 st, 2015
2 Funding
3 Modeling Team Université Laval Jean-François Laprise Mélanie Drolet Talia Malagon CDC Harrell Chesson Lauri Markowitz Imperial College Marie-Claude Boily Disclaimer The findings and conclusions expressed are those of the author and do not necessarily represent the official views of the Centers for Disease Control and Prevention (CDC) or the Department of Health and Human Services (DHHS)
4 Context Recent results from a large clinical trial have shown that a 9-valent HPV vaccine is highly effective 1 Published Feb 19 th in the New England Journal of Medicine 1 9-valent includes types HPV-6/11/16/18/31/33/45/52/58 HPV types that cause about 90% of cervical cancers worldwide 2 9-valent HPV vaccine (Gardasil 9) was approved by: U.S. FDA (December 10 th, 2014) Health Canada (February 5 th, 2015) Thursday (Feb 26 th ), the Advisory Committee on Immunization Practices (ACIP) will vote on whether to recommend 9-valent HPV vaccination in the U.S. REF: 1) Joura, NEJM 2015; 2) de Sanjose, Lancet Oncol 2010
5 9-valent HPV vaccine efficacy Phase III study 9-valent (n=7,099) vs Quadrivalent (n=7,105) Population at enrollment: year old females, not infected Results outcomes with HPV types 31, 33, 45, 52, 58 97% efficacy (95%CI:81-100) against incidence of high-grade cervical/vulvar/vaginal disease caused by HPV types 31, 33, 45, 52, 58 97% efficacy (95%CI:92-99) against incidence of any grade 96% efficacy (95%CI:94-97) against six-month persistent HPV infection What we don t know Added benefit in the context of potential cross-protection REF: Joura, NEJM 2015
6 Main criteria considered when making recommendations for new vaccines Safety & Efficacy Preventable burden of illness Effectiveness & Cost-effectiveness Affordability & Programmatic feasibility Equity Public preferences & Politics
7 Objectives To evaluate the: additional population-level effectiveness, and incremental cost-effectiveness of switching from the 4-valent to the 9-valent HPV vaccine, using the U.S. as an example 7
8 Model Overview HPV-ADVISE Model type: Individual-based transmission-dynamic model & Components: Demographic Sexual behaviour & HPV transmission Natural history of disease Vaccination Screening & Treatment Economic Population: Open-Stable, 10 to 100 years of age HPV infections: 18 genotypes, including 6/11/16/18/31/33/45/52/58 Diseases: Anogenital warts Cervical cancer (SCC & adenocarcinoma) Cancers of the anus, oropharynx, penis, vagina & vulva &: Van de Velde et al. JNCI (22): ; Description of model components in extra slides 8
9 Model fit Results 200,000 different combinations of parameters sampled from the prior parameter distributions 50 parameter sets produced model results within the 826 pre-specified data targets
10 Proportion of sexually active women Model Fit sexual behaviour Ex: Proportion sexually active women Data Box plots represent the min, max and median of model predictions Age (years) &: Other examples of model fit in extra slides; Data: NHANES 10
11 Prevalence HPV-16/18 Prevalence HPV-16/18 Prevalence HPV-16/18 Model Fit HPV Prevalence in women Ex: HPV-16/18 prevalence by age and level of sexual activity 30% 25% Low Sexual Activity (L0) 30% 25% Average Sexual Activity (L1) 20% 20% 15% 15% 10% 10% 5% 5% 0% 40% 35% Age (years) High Sexual Activity (L2) 0% Age (years) 30% 25% 20% Data 95%CI Box plots represent the min, max and median of model predictions 15% 10% 5% 0% Age (years) &: Other examples of model fit in extra slides; Data: NHANES 11
12 Incidence of HSIL per 100,000w-y Model Fit Screening Ex: Incidence of HSIL 1, Data Box plots represent the min, max and median of model predictions Age (years) &: Other examples of model fit in extra slides; Data: Insigna
13 Incidence of SCC per 100,000w-y Model Fit Squamous cell carcinoma (SCC) Ex: Incidence of SCC Data Box plots represent medians, and 5, 25, 75, and 95th percentiles Age group (years) &: Other examples of model fit in extra slides; Data: US Cancer Statistics (NPCR/SEER) 13
14 Vaccine efficacy (VE) parameters VE among susceptible females & males 4-valent Base case VE persistent infection (%) 4-valent & 9-valent HPVtype (no cross protection) (cross protection) 16/ / Other HRtypes &: Malagón, Lancet Infectious Disease 2012 : We assume that VE against HPV-16/18 is equal for the 4- and 9-valent vaccines (based on immunogenicity presented at Eurogin 2013) 14
15 Intervention HPV vaccination Decision 4-valent 4-valent 3-dose vaccination 15
16 Intervention HPV vaccination Decision 4-valent 4-valent 4-valent 16
17 Intervention HPV vaccination Decision 9-valent 9-valent 4-valent 4-valent 4-valent 4-valent 17
18 % vaccinated with 3 doses 3-dose Vaccination Coverage Data: National Immunization Survey Used age-specific 3-dose uptake rates: Annual % vaccinated with 3 rd dose among those who had not previously received a 3 rd dose : Observed uptake rates 2014+: Assumed uptake rates constant at 2013 levels Overall vaccination coverage increases until 2017 due to age and time cohort effects 50% 40% 30% 20% 10% 0% Coverage year olds Girls Boys Year 39% 14% 46% 25% Coverage Age (yrs) Girls Boys 13 26% 12% 14 38% 18% 15 48% 27% 16 55% 31% 17 62% 38% 13 to 17 46% 25% 18
19 Population-level effectiveness 19
20 HPV-type specific positivity 9-valent HPV vaccine Potential for additional cancer prevention 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 31/33/45/52/58 16/18 Women Men 0% Cervix Vulva Vagina Anus Oropharynx Penis Anus Oropharynx &: 1) Saraiya, JNCI (under review) 20
21 Number of cases per year 9-valent HPV vaccine Potential for additional cancer prevention in the U.S. 12,000 Women Men 10,000 8,000 31/33/45/52/58 16/18 6,000 4,000 2,000 0 Cervix Vulva Vagina Anus Oropharynx Penis Anus Oropharynx Ref: 1) Jemal JNCI 2013; 2) Saraiya, JNCI (under review) 21
22 % Change in incidence Effectiveness 4-valent vs. 9-valent Base case, No Cross Protection for 4-valent 0% CIN2/3 0% Cervical Cancer -10% -20% -10% -20% -30% -40% -50% -60% -70% -80% 61% -30% -40% -50% -60% -70% 19% 14% -80% 65% -90% -100% -90% -100% valent (No Cross Protection) 9-valent Years since start of vaccination Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 22
23 % Change in incidence Effectiveness 4-valent vs. 9-valent Base case, with & without Cross Protection for 4-valent 0% CIN2/3 0% Cervical Cancer -10% -20% -30% -40% -50% -60% -10% -20% -30% -40% -50% -60% -70% -80% -90% -100% 12% -70% -80% -90% -100% % 4-valent (No Cross Protection) 4-valent (Cross Protection) 9-valent Years since start of vaccination Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 23
24 % Change in incidence Effectiveness 9-valent vs. 9-valent Girls & 4-valent Boys Base case, No Cross Protection for 4-valent 0% CIN2/3 0% Cervical Cancer -10% -20% -30% -40% -10% -20% -30% -40% -50% -60% -70% -50% -60% -70% 0-1% -80% -90% -100% -80% -90% -100% % 4-valent (No Cross Protection) 9-valent Girls & 4-valent Boys (No Cross Cross Protection Protection) 9-valent Years since start of vaccination Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 24
25 % Change in incidence Effectiveness Base case, No Cross Protection for 4-valent 0% Oropharyngeal Cancer 0% Anogenital warts -10% -20% -30% -40% -50% -60% -70% -10% -20% -30% -40% -50% -60% -70% -80% -90% -100% 4-valent No Cross Protection 9-valent Girls & 4-valent Boys No Cross Protection 9-valent -80% -90% -100% valent 9-valent Years since start of vaccination Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 25
26 Number of events averted (Thousands) Health Outcomes Prevented over 70 years Base case valent (No Cross Protection) 4-valent (Cross Protection) 9-valent Girls & 4-valent Boys (No Cross Protection) 9-valent 0 All Cancers Deaths Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 26
27 Number of events averted (Thousands) Health Outcomes Prevented over 70 years Base case, No Cross Protection for 4-valent 800 NNV & =1, K valent (No Cross Protection) 4-valent (Cross Protection) 9-valent Girls & 4-valent Boys (No Cross Protection) 9-valent 300 NNV=4, K All Cancers Deaths &: NNV=(# females vaccinated with 9-valent) (Additional events prevented by vaccinating females with 9-valent); Base case: vaccine-type efficacy=95%, duration=lifelong; Predictions: Mean estimate generated by the 50 best fitting parameter sets 27
28 Number of events averted (Thousands) Health Outcomes Prevented over 70 years Base case, with Cross Protection for 4-valent 800 NNV & =2, K valent (No Cross Protection) 4-valent (Cross Protection) 9-valent Girls & 4-valent Boys (No Cross Protection) 9-valent K NNV=6, All Cancers Deaths &: NNV=(# females vaccinated with 9-valent) (Additional events prevented by vaccinating females with 9-valent); Base case: vaccine-type efficacy=95%, duration=lifelong; Predictions: Mean estimate generated by the 50 best fitting parameter sets 28
29 Number of events averted (Thousands) Health Outcomes Prevented over 70 years Base case, 9-valent vs. 9-valent Girls & 4-valent Boys 800 NNV & =13, valent valent (No Cross Protection) 4-valent (Cross Protection) 9-valent Girls & 4-valent Boys (No Cross Protection) 300 NNV=32, All Cancers Deaths &: NNV=(# boys vaccinated with 9-valent) (Additional events prevented by vaccinating boys with 9-valent); Base case: vaccine-type efficacy=95%, duration=lifelong; Predictions: Mean estimate generated by the 50 best fitting parameter sets 29
30 % Change in incidence Effectiveness 4-valent vs. 9-valent Australia (switch to 9-valent in 2015, Cross Protection) 0% CIN2/3 0% Cervical Cancer -10% -20% -30% -40% -50% -60% -70% -10% -20% -30% -40% -50% -60% -70% -80% -90% 19% -80% -90% 4-valent Australia 9-valent Australia 14% -100% -100% Years since start of vaccination Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 10 best fitting parameter sets 30
31 Summary Population-level effectiveness predictions Current 4-valent vaccination strategies are expected to substantially reduce HPV-related diseases Switching to a 9-valent strategy is expected to further reduce precancerous lesions and cervical cancer, with less impact on other HPV-related outcomes Vaccinating girls with the 9-valent provides the great majority of benefits of a 9-valent program 31
32 Cost-effectiveness 32
33 Economic analysis Perspective: Costs: Outcome Measure: Discounting: Time Horizon: Vaccine Cost : (with administration) Societal All direct medical costs & Cost per QALY gained & 3% for costs and benefits 70 years 4-valent: $145/dose 9-valent: $158/dose QALY=quality-adjusted life-year &: Description of parameters and references available in extra slides : Cost from Merck presentation at the 29th International Papillomavirus Conference,
34 Incremental QALY-gained (1,000) Incremental QALYs-gained Discounted over 70 years 1,200 1,000 AGW consultations Other cancers Cervical lesions Cervical cancer 800 (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] No Cross Protection 9-valent [3 vs 2] No Cross Protection, 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] Cross Protectcon 9-valent [3 vs 2] Cross Protection, 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 34
35 Incremental QALY-gained (1,000) Incremental QALYs-gained Discounted over 70 years 1,200 1,000 AGW consultations Other cancers Cervical lesions Cervical cancer 800 (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] No Cross Protection 9-valent [3 vs 2] No Cross Protection, 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] Cross Protectcon 9-valent [3 vs 2] Cross Protection, 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 35
36 Incremental QALY-gained (1,000) Incremental QALYs-gained Discounted over 70 years 1,200 1,000 AGW consultations Other cancers Cervical lesions Cervical cancer 800 (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] No Cross Protection 9-valent [3 vs 2] No Cross Protection, 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] Cross Protectcon 9-valent [3 vs 2] Cross Protection, 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 36
37 Incremental QALY-gained (1,000) Incremental QALYs-gained Discounted over 70 years 1,200 1,000 AGW consultations Other cancers Cervical lesions Cervical cancer 800 (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] No Cross Protection 9-valent [3 vs 2] No Cross Protection, 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] Cross Protectcon 9-valent [3 vs 2] Cross Protection, 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong Predictions: Mean estimate generated by the 50 best fitting parameter sets 37
38 Incremental Cost offsets ($1,000,000) Incremental Healthcare costs saved Discounted over 70 years 25,000 22,500 20,000 17,500 15,000 12,500 10,000 7,500 5,000 2,500 AGW consultations Other cancers Cervical screening Cervical cancer (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent 0 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] No Cross No Protection, Cross 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] Cross Protection, Cross Protectcon 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean estimate generated by the 50 best fitting parameter sets 38
39 Incremental Cost offsets ($1,000,000) Incremental Healthcare costs saved Discounted over 70 years 25,000 22,500 20,000 17,500 15,000 12,500 10,000 7,500 5,000 2,500 AGW consultations Other cancers Cervical screening Cervical cancer (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent 0 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] No Cross No Protection, Cross 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] Cross Protection, Cross Protectcon 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean estimate generated by the 50 best fitting parameter sets 39
40 Incremental Cost offsets ($1,000,000) Incremental Healthcare costs saved Discounted over 70 years 25,000 22,500 20,000 17,500 15,000 12,500 10,000 7,500 5,000 2,500 AGW consultations Other cancers Cervical screening Cervical cancer (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent 0 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] No Cross No Protection, Cross 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] Cross Protection, Cross Protectcon 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean estimate generated by the 50 best fitting parameter sets 40
41 Incremental Cost offsets ($1,000,000) Incremental Healthcare costs saved Discounted over 70 years 25,000 22,500 20,000 17,500 15,000 12,500 10,000 7,500 5,000 2,500 AGW consultations Other cancers Cervical screening Cervical cancer (1) 4-valent (2) 9-valent Girls, 4-valent Boys (3) 9-valent 0 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] No Cross No Protection, Cross 4-valent 4-valent [1 vs No vacc] 9-valent Girls 4-valent Boys [2 vs 1] 9-valent [3 vs 2] Cross Protection, Cross Protectcon 4-valent Base case: vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean estimate generated by the 50 best fitting parameter sets 41
42 Cost-effectiveness Base Case, No Cross Protection for 4-valent Change in costs ($ million) Change in QALY-gained (1,000 QALY) ICER ($/QALYgained) (0) No Vaccination (1) 4-valent 1 vs. 0 6,866 1,068 6,400 [3,500; 10,100] (2) 9-valent Girls 4-valent Boys 2 vs. 1-2, Cost saving [CS; CS] (3) 9-valent 3 vs ,200 [1,900; >1million] 3 vs. 1-2, Cost saving [CS; CS] ICER: Incremental Cost-Effectiveness Ratio; QALY=quality-adjusted life-year Base case: Vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean result of the 50 best fitting parameter sets (25 runs per parameter set) Uncertainty intervals: 10 th and 90 th percentiles of model results based on the 50 best fitting parameter sets, reflects uncertainty in the natural history parameters 42
43 Cost-effectiveness Base Case, No Cross Protection for 4-valent Change in costs ($ million) Change in QALY-gained (1,000 QALY) ICER ($/QALYgained) (0) No Vaccination (1) 4-valent 1 vs. 0 6,866 1,068 6,400 [3,500; 10,100] (2) 9-valent Girls 4-valent Boys 2 vs. 1-2, Cost saving [CS; CS] (3) 9-valent 3 vs ,200 [1,900; >1million] 3 vs. 1-2, Cost saving [CS; CS] ICER: Incremental Cost-Effectiveness Ratio; QALY=quality-adjusted life-year Base case: Vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean result of the 50 best fitting parameter sets (25 runs per parameter set) Uncertainty intervals: 10 th and 90 th percentiles of model results based on the 50 best fitting parameter sets, reflects uncertainty in the natural history parameters 43
44 Cost-effectiveness Base Case, No Cross Protection for 4-valent Change in costs ($ million) Change in QALY-gained (1,000 QALY) ICER ($/QALYgained) (0) No Vaccination (1) 4-valent 1 vs. 0 6,866 1,068 6,400 [3,500; 10,100] (2) 9-valent Girls 4-valent Boys 2 vs. 1-2, Cost saving [CS; CS] (3) 9-valent 3 vs ,200 [1,900; >1million] 3 vs. 1-2, Cost saving [CS; CS] ICER: Incremental Cost-Effectiveness Ratio; QALY=quality-adjusted life-year Base case: Vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean result of the 50 best fitting parameter sets (25 runs per parameter set) Uncertainty intervals: 10 th and 90 th percentiles of model results based on the 50 best fitting parameter sets, reflects uncertainty in the natural history parameters 44
45 Cost-effectiveness Base Case, No Cross Protection for 4-valent Change in costs ($ million) Change in QALY-gained (1,000 QALY) ICER ($/QALYgained) (0) No Vaccination (1) 4-valent 1 vs. 0 6,866 1,068 6,400 [3,500; 10,100] (2) 9-valent Girls 4-valent Boys 2 vs. 1-2, Cost saving [CS; CS] (3) 9-valent 3 vs ,200 [1,900; >1million] 3 vs. 1-2, Cost saving [CS; CS] ICER: Incremental Cost-Effectiveness Ratio; QALY=quality-adjusted life-year Base case: Vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean result of the 50 best fitting parameter sets (25 runs per parameter set) Uncertainty intervals: 10 th and 90 th percentiles of model results based on the 50 best fitting parameter sets, reflects uncertainty in the natural history parameters 45
46 Cost-effectiveness Base Case, No Cross Protection for 4-valent Change in costs ($ million) Change in QALY-gained (1,000 QALY) ICER ($/QALYgained) (0) No Vaccination (1) 4-valent 1 vs. 0 6,866 1,068 6,400 [3,500; 10,100] (2) 9-valent Girls 4-valent Boys 2 vs. 1-2, Cost saving [CS; CS] (3) 9-valent 3 vs ,200 [1,900; >1million] 3 vs. 1-2, Cost saving [CS; CS] ICER: Incremental Cost-Effectiveness Ratio; QALY=quality-adjusted life-year Base case: Vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean result of the 50 best fitting parameter sets (25 runs per parameter set) Uncertainty intervals: 10 th and 90 th percentiles of model results based on the 50 best fitting parameter sets, reflects uncertainty in the natural history parameters 46
47 Cost-effectiveness Base Case, with Cross Protection for 4-valent Change in costs ($ million) Change in QALY-gained (1,000 QALY) ICER ($/QALYgained) (0) No Vaccination (1) 4-valent 1 vs. 0 5,379 1,131 4,800 [1,600; 8,600] (2) 9-valent Girls 4-valent Boys 2 vs. 1-1, Cost saving [CS; CS] (3) 9-valent 3 vs ,400 [4,000;>1million] 3 vs Cost saving [CS; 10,400] ICER: Incremental Cost-Effectiveness Ratio; QALY=quality-adjusted life-year Base case: Vaccine-type efficacy=95%, duration=lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Predictions: Mean result of the 50 best fitting parameter sets (25 runs per parameter set) Uncertainty intervals: 10 th and 90 th percentiles of model results based on the 50 best fitting parameter sets, reflects uncertainty in the natural history parameters 47
48 Results: Sensitivity Analysis Influential Variables 48
49 Sensitivity Analysis Incremental cost-effectiveness ($/QALYgained), with Cross Protection for 4-valent 4-valent () vs. No vaccination 9-valent () vs 4-valent () Base case 4,800 Cost saving Duration of Protection 9- & 4-valent=20yrs Cross-protection=20yrs Vaccination Coverage All doses at 13 yrs of age Girls=75%, Boys=69% 6,500 4,900 6,700 9,900 Cost saving Cost saving Cost saving 3,500 Min Health Care Costs 11,700 4,500 Min Burden of Disease 8,000 Cost saving Cervical screening - Co-testing - Cost saving ICER: Incremental Cost-Effectiveness Ratio; QALY=quality-adjusted life-year Base case: Vaccine-type efficacy=95%, duration of protection =Lifelong; 4-valent cost/dose=$145; 9-valent cost/dose=$158 Min: Minimum estimates from the U.S. literature; All doses given at 13 yrs of age: Vaccination coverage Girls=62%, Boys=32%; HPV Co-testing: HPV co-testing every 5 years (30-65 year old women) Predictions: Mean result of the 50 best fitting parameter sets (20 runs per parameter set) 49
50 Max. additional cost/dose for the 9-valent to be cost-effective vs. Quadrivalent in Canada (at $40,000/QALY-gained) Girls-only, Coverage=80%, VE=95%, Quadrivalent X- protection Description Cost diff. BASE CASE 24(6;36) Vaccine duration (VD) VD=Life 16(6;26) Lower nonavalent vaccine efficacy (VE) Nona VE=90% 19(10;36) Nona VE=85% 19(10;35) Vaccination coverage (VC) VC=70% 25(16;35) VC=50% 25(16;43) Disease Burden Max. cancer burden 37(10;50) Min. cancer burden 16(5;30) Max. AGW burden 24(7;34) Min. AGW burden 24(6;36) Disease endpoints Cervical cancer and AGW 24(6;35) Cervical cancer only 24(5;36) Cost-effectiveness threshold $20,000 $100,000 Most favourable scenario for quadrivalent Quad: VE=95%, VD=Life; Nona: VE=85%, VD=20yrs 8(-9;19) REF: Drolet, International Journal Cancer (4;21) 49(13;81) Favourable to nonavalent Cost difference ($)
51 Max. additional cost/dose for the 9-valent to be cost-effective vs. Quadrivalent in Canada (at $40,000/QALY-gained) Girls-only, Coverage=80%, VE=95%, Quadrivalent X- protection Description Cost diff. BASE CASE 24(6;36) Vaccine duration (VD) VD=Life 16(6;26) Lower nonavalent vaccine efficacy (VE) Nona VE=90% 19(10;36) Nona VE=85% 19(10;35) Vaccination coverage (VC) VC=70% 25(16;35) VC=50% 25(16;43) Disease Burden Max. cancer burden 37(10;50) Min. cancer burden 16(5;30) Max. AGW burden 24(7;34) Min. AGW burden 24(6;36) Disease endpoints Cervical cancer and AGW 24(6;35) Cervical cancer only 24(5;36) Cost-effectiveness threshold $20,000 $100,000 Most favourable scenario for quadrivalent Quad: VE=95%, VD=Life; Nona: VE=85%, VD=20yrs 8(-9;19) REF: Drolet, International Journal Cancer (4;21) 49(13;81) Favourable to nonavalent Cost difference ($)
52 Summary 52
53 Summary Cost-effectiveness predictions Current 4-valent HPV vaccination programs are highly costeffective Switching to a 9-valent program is likely cost-effective (and cost saving in the U.S.) Vaccinating girls with the 9-valent provides the majority of cost savings and QALYs-gained of a 9-valent program Results are robust across a range of plausible assumptions with or without cross protection vaccination coverage, price, duration of protection, health care costs, burden of illness 53
54 Thank you! 54
IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION
IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION Marc Brisson Full Professor Université Laval, Canada SAGE meeting October 24, 2018 Geneva 1 Questions A. What is the potential
More informationSAGE evidence to recommendations framework i
SAGE evidence to recommendations framework i Question: What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old
More informationb de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY
b de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY Human papillomaviruses (HPV) are common sexually transmitted viruses. They can cause several types
More informationAn update on the Human Papillomavirus Vaccines. I have no financial conflicts of interest. Case 1. Objectives 10/26/2016
An update on the Human Papillomavirus Vaccines Karen Smith-McCune Professor, UCSF Department of Obstetrics, Gynecology and Reproductive Sciences John Kerner Endowed Chair I have no financial conflicts
More informationTECHNICAL APPENDIX HPV-ADVISE CDC
TECHNICAL APPENDIX HPV-ADVISE CDC Brisson, Marc Laprise, Jean-François Drolet, Mélanie Van de Velde, Nicolas Boily, Marie-Claude Marc Brisson, Nicolas Van de Velde, Marie-Claude Boily, 2014-2016. TECHNICAL
More informationCERVICAL CANCER SCREENING SCENARIOS for pan-canadian Cervical Screening Initiative
CERVICAL CANCER SCREENING SCENARIOS for pan-canadian Cervical Screening Initiative June 18 2014 Acknowledgements Anthony Miller Cathy Popadiuk Claude Nadeau Keiko Asakawa Marc Brisson Michael Wolfson Saima
More informationThe HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland
The HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland Immunisations Very cost effective intervention Give vaccine before exposure to disease UK has life course approach
More informationSchedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE
1 Schedules and strategies for HPV immunization Conclusions and proposed recommendations for SAGE Andrew Pollard, SAGE Member SAGE meeting, 18 20 October 2016 Questions for SAGE 2 1. What is the incremental
More informationEstimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
Boiron et al. BMC Infectious Diseases (2016) 16:153 DOI 10.1186/s12879-016-1483-5 RESEARCH ARTICLE Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV
More informationTrends in HPV-Associated Cancers United States,
National Center for Chronic Disease Prevention and Health Promotion Trends in HPV-Associated Cancers United States, 1999 2014 Elizabeth A. Van Dyne, MD, MPH Division of Cancer Prevention and Control Epidemiology
More informationVaccine 26S (2008) F3 F15. Contents lists available at ScienceDirect. Vaccine. journal homepage:
Vaccine 26S (2008) F3 F15 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Review Evolution of the health economics of cervical cancer vaccination Nicole
More informationTowards the elimination of HPV
Towards the elimination of HPV Richard Hillman June 11th 2018 Potential conflicts of interest Potential Conflicts of Interest Declaration CSL research + travel + support for student MSD International Scientific
More informationPreventive Vaccines against HPV. Paris, 2 April 2015 Yvonne Deleré, MD (former) Immunization Unit, Robert Koch Institute, Berlin
Preventive Vaccines against HPV Paris, 2 April 2015 Yvonne Deleré, MD (former) Immunization Unit, Robert Koch Institute, Berlin Content 1. HPV associated diseases 2. Preventivevaccines Efficacy Safety
More informationRESEARCH. Economic evaluation of human papillomavirus vaccination in the United Kingdom
Economic evaluation of human papillomavirus vaccination in the United Kingdom Mark Jit, health economist and mathematical modeller, Yoon Hong Choi, mathematical modeller, WJohnEdmunds,headofmodellingandeconomicsunit
More informationEvaluating Human Papillomavirus (HPV) Vaccination Strategies in Canada using the Cancer Risk Management HPV Microsimulation Model (CRM-HPVMM)
Evaluating Human Papillomavirus (HPV) Vaccination Strategies in Canada using the Cancer Risk Management HPV Microsimulation Model (CRM-HPVMM) ARCC Conference Monday, May 27, 2013 Presented by William Flanagan
More informationBUST MYTHS WITH FACTS
Myths & Facts Death too early BUST MYTHS Not my child WITH FACTS Awkward Conversation Autism TOOLS: Just the Facts Provider Audience http://bit.ly/vacsjustthefacts TOOLS: Addressing Parent s Top Questions
More informationHPV-Associated Disease and Prevention
HPV-Associated Disease and Prevention Odessa Regional Medical Center May 28, 2015 Erich M. Sturgis, MD, MPH Professor Department of Head & Neck Surgery Department of Epidemiology Christopher & Susan Damico
More informationObjectives. HPV Classification. The Connection Between Human Papillomavirus and Oropharyngeal Cancer 6/19/2012
The Connection Between Human Papillomavirus and Oropharyngeal Cancer Jennifer L. Cleveland, DDS, MPH Dental Officer/Epidemiologist OSAP Annual Symposium June 23, 2012 Atlanta, GA National Center for Chronic
More informationPapillomavirus Rapid Interface for Modelling and Economics Tool. User Manual
Papillomavirus Rapid Interface for Modelling and Economics Tool User Manual List of abbreviations DALYs disability adjusted life years GDP HPV IARC gross domestic product human papillomavirus International
More informationHPV-Associated Cancers
HPV-Associated Cancers HPV Vaccination Summit: Debunking Myths and Preventing Cancer Thursday, February 2, 2017 St. Luke s Anderson Center Chris Johnson, MPH Cancer Data Registry of Idaho Outline Human
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationInforming HPV vaccination strategy about target groups: girls-only, gender-neutral, catch-up and selective adult vaccination
Informing HPV vaccination strategy about target groups: girls-only, gender-neutral, catch-up and selective adult vaccination Johannes A Bogaards, PhD National Institute for Public Health and the Environment,
More informationDr. Unjali Malhotra Women s Health updates. Program Director UBC Women s Health Chair Canadian Foundation for Women s Health
Dr. Unjali Malhotra Women s Health updates CCFP Women s Health FCFP NCMP Program Director UBC Women s Health Chair Canadian Foundation for Women s Health HPV The ANTI CANCER Vaccines QUADrivalent HPV Vaccine
More informationYou are the Key to HPV Cancer Prevention
AHEC Logo here You are the Key to HPV Cancer Prevention Understanding the Burden of HPV Disease, the Importance of the HPV Vaccine Recommendation, and Communicating about HPV Vaccination Aubrey Stetter-Hesselberg,
More informationSAGE evidence to recommendations framework i
SAGE evidence to recommendations framework i Question: In 9 to 15-year old females, is 9-valent human papillomavirus vaccine (HPV) vaccine superior to 4-valent or 2-valent HPV vaccines? Population: 9 to
More informationAnal Cancer and HPV Related Tumor Prevention
Anal Cancer and HPV Related Tumor Prevention Timothy J. Wilkin, MD, MPH Associate Professor of Medicine Weill Cornell Medicine New York, New York Learning Objectives After attending this presentation,
More informationHPV FREE IDAHO. Fundamentals of HPV Bill Atkinson, MD MPH
HPV FREE IDAHO Fundamentals of HPV Bill Atkinson, MD MPH You are the Key to HPV Cancer Prevention William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition February
More informationKate T Simms, Jean-François Laprise, Megan A Smith, Jie-Bin Lew, Michael Caruana, Marc Brisson, Karen Canfell
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis Kate T Simms, Jean-François
More informationRecommendations for Human Papillomavirus Vaccination Provincial Infectious Diseases Advisory Committee on Immunization
Recommendations for Human Papillomavirus Vaccination Provincial Infectious Diseases Advisory Committee on Immunization June 11, 2012 i This document was prepared for the Provincial Infectious Diseases
More informationHPV Prevention: Where Are We and Where Do We Need to Go. Rachel Caskey, MD MAPP
HPV Prevention: Where Are We and Where Do We Need to Go Rachel Caskey, MD MAPP Assistant Professor of Internal Medicine and Pediatrics University of Illinois at Chicago Disclosures I have no financial
More informationQuestions and answers about HPV. Facts about the virus and the vaccine
Questions and answers about HPV Facts about the virus and the vaccine About the introduction of the human papillomavirus (HPV) vaccine Which countries have introduced the HPV vaccine? Over 100 countries
More informationUpdate of the role of Human Papillomavirus in Head and Neck Cancer
Update of the role of Human Papillomavirus in Head and Neck Cancer 2013 International & 12 th National Head and Neck Tumour Conference Shanghai, 11 13 Oct 2013 Prof. Paul KS Chan Department of Microbiology
More informationWednesday, March 16, 2016
You are the Key to HPV Cancer Prevention Understanding the Burden of HPV Disease, the Importance of the HPV Vaccine Recommendation, and Communicating about HPV Vaccination Bea Himmelwright-Lamm, EdD, RN
More informationHPV Vaccine Ina Park, MD, MS
HPV Vaccine Ina Park, MD, MS California Department of Public Health STD Control Branch Alameda County Immunization Update 2014 Over 170 types of HPV classified Updated incidence/prevalence estimates (CDC):
More informationHPV-Related Head and Neck Squamous Cancers
2015 Wisconsin Comprehensive Cancer Control Summit Aligning Partners, Priorities, and the Plan HPV-Related Head and Neck Squamous Cancers MCW Department of Otolaryngology and Communication Sciences MCW
More informationComparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine Advisory Committee on Immunization Practices 24-Feb-2016
1 Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent HPV vaccine Advisory Committee on Immunization Practices 24-Feb-2016 Presenter: Alain Luxembourg, MD, PhD Director, Clinical Research
More informationAmber L Pearson 1*, Giorgi Kvizhinadze 1, Nick Wilson 1, Megan Smith 2, Karen Canfell 2 and Tony Blakely 1
Pearson et al. BMC Infectious Diseases 2014, 14:351 RESEARCH ARTICLE Open Access Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis
More informationAnna R Giuliano, PhD Center for Infection Research in Cancer Moffitt Cancer Center
Towards the Elimination of HPV- Related Disease: Starting with Cervical Cancer Anna R Giuliano, PhD Center for Infection Research in Cancer Moffitt Cancer Center Conflicts of Interest Dr. Giuliano reports
More informationPrimary prevention of cervical cancer through HPV vaccination what is the future?
Primary prevention of cervical cancer through HPV vaccination what is the future? Lynette Denny Department of Obstetrics & Gynaecology, University of Cape Town/Groote Schuur Hospital, Cape Town, South
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationFocus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010
HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,
More informationYou are the Key to HPV Cancer Prevention Understanding the Burden of HPV Disease, the Importance of the HPV Vaccine Recommendation, and Successfully
You are the Key to HPV Cancer Prevention Understanding the Burden of HPV Disease, the Importance of the HPV Vaccine Recommendation, and Successfully Communicating about HPV Vaccination Disclosure This
More informationProfessor Margaret Stanley
19 th Annual Conference of the British HIV Association (BHIVA) Professor Margaret Stanley University of Cambridge 16-19 April 2013, Manchester Central Convention Complex 19 th Annual Conference of the
More informationCervical Cancer The Role of Primary Care in Reducing Cancer Disparities
Cervical Cancer The Role of Primary Care in Reducing Cancer Disparities March 28, 2015 Electra D. Paskett, Ph.D. The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and
More informationUpdate on Cervical Cancer Screening. Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationUpdate on Cervical Cancer Screening
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationCervical screening. Cytology-based screening programmes
HPV-FASTER: broadening the scope for prevention of HPV-related cancer Combining the complementary approaches of HPV vaccination and screening could accelerate declines in the burden of cervical cancer
More informationHPV vaccine acceptance in male adolescents
HPV vaccine acceptance in male adolescents Prue, G., & Santin, O. (2015). HPV vaccine acceptance in male adolescents. Psycho-Oncology, 24(10), 1327-1329. DOI: 10.1002/pon.3961 Published in: Psycho-Oncology
More informationHuman papillomavirus and vaccination for cervical cancer
Human papillomavirus and vaccination for cervical cancer Dorothy Machalek Department of Microbiology and Infectious Diseases Royal Women s Hospital, Melbourne, Australia VIRUSES AND CANCER Responsible
More informationSelling Parents on HPV Vaccination for Their Preteens: You Are The Key
Selling Parents on HPV Vaccination for Their Preteens: You Are The Key November 7, 2014 Jill B Roark, MPH Lead, Adolescent Immunization Communications Health Communication Science Office National Center
More informationObjectives. Selling Parents on HPV Vaccination for Their Preteens: You Are The Key. HPV Facts TOP TEN List. Disclosure
11/12/214 Objectives Selling Parents on HPV Vaccination for Their Preteens: You Are The Key November 7, 214 Jill B Roark, MPH Lead, Adolescent Immunization Communications Health Communication Science Office
More informationInnovations in Human Papillomavirus Vaccine
Oct 2014 Life Health Innovations in Human Papillomavirus Vaccine Innovation 1 Topics 1. Current HPV vaccines 2. New development 3. What s next? 2 PART I CURRENT HPV VACCINES 3 Worldwide incidence of cervical
More informationEvidence-Based HPV Disease Prevention HPV VACCINE
Evidence-Based HPV Disease Prevention HPV VACCINE Educating and normalizing vaccine compliance for the teen population Leisha Nolen, MD PhD Enroll in Electronic Poll System In the texting app in your phone:
More informationGUIDELINES FOR POLICY PAPERS SUBMITTED TO THE HOUSE OF DELEGATES
GUIDELINES FOR POLICY PAPERS SUBMITTED TO THE HOUSE OF DELEGATES Resolution Deadline: March 20, 2018 The purpose of this document is to provide standard guidelines for the submission of policy papers to
More informationExpanded Eligibility for Human Papillomavirus (HPV) Vaccination for Select Male Populations Q&A Document August 2015
Expanded Eligibility for Human Papillomavirus (HPV) Vaccination for Select Male Populations Q&A Document August 2015 1. Can you tell me more about the expanded eligibility criteria for HPV vaccination?
More informationReal-life challenges in implementing public strategies for HPV vaccination in developing countries, and strategies to increase immunization coverage
Real-life challenges in implementing public strategies for HPV vaccination in developing countries, and strategies to increase immunization coverage Prof. Charbell Miguel Haddad Kury, MD Pediatrician Infectious
More informationHPV/Cervical Cancer Resource Guide for patients and providers
DHS: PUBLIC HEALTH DIVISION IMMUNIZATION PROGRAM HPV/Cervical Cancer Resource Guide for patients and providers Independent. Healthy. Safe. Oregon HPV Provider Resource Kit: Table of Contents Provider Information
More informationHPV Vaccination: Educating and Empowering the Next Generation
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 HPV Vaccination: Educating and Empowering the Next Generation Sruthi Sakamuri University
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationHPV doesn t concern men?
Think HPV doesn t concern men? What you should know about HPV-related cancers and genital warts. One infected partner may be all it takes to get HPV. HPV=human papillomavirus Trying to decide if GARDASIL
More informationHPV Vaccines. What is HPV? Can a vaccine help prevent HPV?
What is HPV? HPV Vaccines HPV is short for human papilloma virus. HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, which is called an HPV type. HPVs are
More informationHIV-1 Vaccine Development Clinical Trials and Public Health Benefits Chaiyos Kunanusont HIV/AIDS Adviser United Nations Population Fund
The 2 nd Advanced Vaccinology course (NVCO) DDC, Radisson Bangkok 15 17 June 2010 HIV-1 Vaccine Development Clinical Trials and Public Health Benefits Chaiyos Kunanusont HIV/AIDS Adviser United Nations
More informationUpdate on Anal HPV. Medical Management of AIDS. December 9, Joel Palefsky Department of Medicine University of California, San Francisco
Update on Anal HPV Medical Management of AIDS December 9, 2017 Joel Palefsky Department of Medicine University of California, San Francisco Disclosures Merck and Co- research and travel support Antiva
More informationDe-Sexualizing the HPV Vaccine How to Counsel Your Families
De-Sexualizing the HPV Vaccine How to Counsel Your Families Laura J. Benjamins, MD, MPH Assistant Professor, Adolescent Medicine The University of Texas Medical School, Houston Objectives Understand current
More informationOPPORTUNISTIC HPV VACCINATION: AN EXPANDED VISION
OPPORTUNISTIC HPV VACCINATION: AN EXPANDED VISION SUMMARY POSITION Human papillomavirus (HPV) infection is preventable but not adequately prevented. At present, Canada has a robust school vaccination program
More informationCervical cancer screening in vaccinated population
Cervical cancer screening in vaccinated population Cytology and molecular testing Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol Izmir, November
More informationThe Global Burden of HPV Related Cancers and Their Prevention
The Global Burden of HPV Related Cancers and Their Prevention What Every Doctor Should Know! Dr. Adrian Lear, MD Conflict of Interest Disclosure I have no financial relations with any commercial entity
More informationUPDATE ON NONAVALENT HPV VACCINE KA YU TSE
UPDATE ON NONAVALENT HPV VACCINE KA YU TSE Outline HPV and related diseases HPV vaccines review 9-valent HPV vaccines HPV-RELATED DISEASES What is HPV? Non-enveloped virus containing double-stranded circular
More informationHuman Papillomavirus among Gay and Bisexual Men: The Need for Education and Vaccination 2012
University of Rhode Island DigitalCommons@URI Lesbian Gay Bisexual Transgender Queer Center The Community, Equity, & Diversity Collections 2012 Human Papillomavirus among Gay and Bisexual Men: The Need
More informationThe Introduction of Primary HPV Screening in Australia
The Introduction of Primary HPV Screening in Australia Dr Louise Farrell Member: Steering Committee Renewal Implementation Project National Cervical Screening Program, Department of Health Australia Head
More informationHPV Vaccination. Dr. Vivien Tsu PATH. HPV Vaccination 1
HPV Vaccination Dr. Vivien Tsu PATH HPV Vaccination 1 HPV vaccine overview 1 First vaccines to focus on a female cancer. Prepared from virus-like particles (VLPs). VLPs are non-infectious. Two vaccines
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationObstacles and opportunities for including males in Canadian human papillomavirus vaccination programs
Obstacles and opportunities for including males in Canadian human papillomavirus vaccination programs Gilla K. Shapiro, Samara Perez, Zeev Rosberger Department of Psychology, McGill University Psychosocial
More informationThe promise of HPV vaccines for Cervical (and other genital cancer) prevention
The promise of HPV vaccines for Cervical (and other genital cancer) prevention CONTROVERSIES IN OBSTETRICS GYNECOLOGY & INFERTILITY Barcelona March 27 F. Xavier Bosch Catalan Institute of Oncology CURRENT
More information12/4/18 HPV VACCINATION IN MASSACHUSETTS AND BEYOND VANUCCI DISCLOSURE OBJECTIVES VACCINE BENEFITS VACCINE COMMUNICATION WORLD
HPV VACCINATION IN MASSACHUSETTS AND BEYOND Rebecca Vanucci, MA 6 th Annual HPV-Related Cancer Summit November 30, 2018 1 2 VANUCCI DISCLOSURE OBJECTIVES I, Rebecca Vanucci, have been asked to disclose
More informationIS39 CP6108 [1]
112 9 26 2017 40 2018:28:112-118 (human papillomavirus, HPV) DNA 100 16 18 31 33 35 39 45 51 52 56 58 59 68 6 11 26 40 42 53 54 55 61 62 64 66 67 69 70 71 72 73 81 82 83 84 IS39 CP6108 ( ) [1] 2012 588,000
More informationHUMAN PAPILLOMAVIRUS
HUMAN PAPILLOMAVIRUS HUMAN PAPILLOMAVIRUS The Human Papillomavirus (HPV) is responsible for 60% of cancers of the throat including base of the tongue and tonsils. AN OVERVIEW TO HUMAN PAPILLOMAVIRUS Human
More informationBattle against Human Papilloma Virus (HPV): Expanded Vaccine Recommendations
Battle against Human Papilloma Virus (HPV): Expanded Vaccine Recommendations Sean W. Clark, Pharm.D. PGY-2 Ambulatory Care Resident Duquesne University and The Center for Pharmacy Care I have no relevant
More informationUICC HPV and CERVICAL CANCER CURRICULUM. UICC HPV and Cervical Cancer Curriculum Chapter 5. Application of HPV vaccines Prof. Suzanne Garland MD
UICC HPV and CERVICAL CANCER CURRICULUM 01 Chapter 5. Application of HPV vaccines Director of Microbiological Research Director of Clinical Microbiology and Infectious Diseases The Royal Women's Hospital
More informationHPV is the most common sexually transmitted infection in the world.
Hi. I m Kristina Dahlstrom, an instructor in the Department of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center. My lecture today will be on the epidemiology of oropharyngeal
More informationHPV vaccine the global perspective
National Immunisation Conference Dublin, 25 May 2018 HPV vaccine the global perspective Robb Butler Vaccine-preventable Diseases and Immunization WHO Regional Office for Europe Presentation outline Burden
More informationCost-effectiveness of Influenza Vaccine
Cost-effectiveness of Influenza Vaccine Lisa A. Prosser, PhD, MS Associate Professor University of Michigan National Influenza Vaccine Summit May 16, 2012 Acknowledgments Funding for this research project
More informationAccess to HPV vaccine widened
Immunisation Medicine subsidy Public Health Sexual Health Access to HPV vaccine widened The human papillomavirus virus (HPV) vaccine reduces the incidence of HPV-related diseases, including genital warts
More informationAn Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)
An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine and clarification of minimum
More informationAn inclusive approach to Human Papilloma Virus vaccination: the case for gender neutral vaccination in Canada
An inclusive approach to Human Papilloma Virus vaccination: the case for gender neutral vaccination in Canada Sabrina Bartolucci, Lilia Brahimi, Allison Hecht, Jasmine Li-Brubacher, Natasha Leblanc, Geneviève
More informationThe Role of Human Papillomavirus Vaccines in Reducing the Risk of Cervical Cancer in Ireland. A Health Technology Assessment
The Role of Human Papillomavirus Vaccines in Reducing the Risk of Cervical Cancer in Ireland A Health Technology Assessment 25 th February 2008 Foreword Cervical cancer is the 8th most frequently diagnosed
More informationThe Importance of HPV Vaccination and Strategies to Increase Uptake in Pediatric & Family Practices
The Importance of HPV Vaccination and Strategies to Increase Uptake in Pediatric & Family Practices Amanda Dempsey, MD, PhD, MPH Associate Professor of Pediatrics Children s Hospital Colorado October,
More informationPotential health and economic impact of adding a human papillomavirus vaccine to screening programs Kulasingam S L, Myers E R
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs Kulasingam S L, Myers E R Record Status This is a critical abstract of an economic evaluation that meets
More informationHIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco
Anal cytology and anal cancer in HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco April 10, 2010 Disclosures Merck and Co: Research grant support, advisory boards
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationHPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge
HPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge 1 Disclosure Statement Dr. Margaret Stanley has acted as a consultant and advisor for Merck Sharp
More informationThe Impact of HPV Vaccination and the Future of Cervical Cancer Screening
UICC Word Cancer Congress 2016 Latest Evidence and Tools for Effective National Cervical Cancer Screening Programs Paris, November 3, 2016 The Impact of HPV Vaccination and the Future of Cervical Cancer
More informationOpportunities and challenges for human papillomavirus vaccination in cancer prevention
Opportunities and challenges for human papillomavirus vaccination in cancer prevention Johannes A Bogaards, PhD National Institute for Public Health and the Environment, The Netherlands VU University Medical
More informationMarc Brisson PhD, Nicolas Van de Velde MSc, Philippe De Wals MD PhD, Marie-Claude Boily PhD
Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection Marc Brisson PhD, Nicolas Van de Velde MSc, Philippe De Wals MD PhD, Marie-Claude Boily
More informationGeorgia State University. Georgia State University. Vaishali Sahu. Summer
Georgia State University ScholarWorks @ Georgia State University Public Health Theses School of Public Health Summer 8-12-2014 An Assessment of Selected Factors Associated with HPV Vaccination Completion
More informationPresenter Disclosure Information
1:30 2:25pm An Update on HPV Cancer Prevention SPEAKERS Kenneth Alexander, MD, PhD Anna Giuliano, PhD Presenter Disclosure Information The following relationships exist related to this presentation: Dr
More informationGARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant
SWISS SUMMARY OF ACTIVITIES IN THE RISK MANAGEMENT PLAN FOR GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant Active Substance: Human Papillomavirus 9-valent Vaccine, Recombinant MAH / MAA
More informationThe comparative impacts of cervical cancer screening guidelines on the overdiagnosis of precancerous lesions in Canada
The comparative impacts of cervical cancer screening guidelines on the overdiagnosis of precancerous lesions in Canada Preventing Overdiagnosis Conference August 17-19, 2017 Quebec City, QC Cindy Gauvreau
More informationOverview of HPV; Making it Real
Overview of HPV; Making it Real Deanna Kepka, PhD, MPH Cancer Control and Population Sciences, Huntsman Cancer Institute College of Nursing, University of Utah November 19, 2016 Objectives: Provide an
More informationUNIVERSITY OF CALGARY. Alberta. Jong Woan Kim A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE
UNIVERSITY OF CALGARY Economic Evaluation of a Human Papillomavirus Vaccination Program for Grade 5 Boys in Alberta by Jong Woan Kim A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT
More information